Line design
Settlement Enjoins Defendants’ Anticompetitive Conduct and Bars Shkreli from the Pharmaceutical Industry for Life

BCBSM, Inc. v. Vyera Pharmaceuticals, LLC et al.

On January 31, 2022, as court-appointed interim lead counsel, Robins Kaplan reached a settlement worth up to $28 million on behalf of indirect purchasers alleging that Martin Shkreli and his former companies illegally monopolized the market for Daraprim—a once-affordable, life-saving drug that increased in price by more than 4,000 percent under Shkreli’s leadership.

In March of 2021, Robins Kaplan filed the first—and only—private lawsuit in the country against Martin Shkreli and his former companies Vyera Pharmaceuticals and Phoenixus AG, as well as Vyera’s former CEO Kevin Mulleady. The firm filed suit on behalf of Blue Cross Blue Shield of Minnesota and a proposed class of health plans that purchased or provided reimbursement for Daraprim, the gold-standard treatment for toxoplasmosis, a parasitic infection that can be fatal for people with compromised immune systems, like those with HIV/AIDS. Plaintiffs alleged that defendants endangered vulnerable patients and overcharged health plans by raising the price of Daraprim from $17.50 to $750 per pill while illegally blocking lower-cost generic versions.

The settlement, approved in June of 2022, provides up to $28 million for third-party payors who were allegedly overcharged because of defendants’ scheme, enjoins defendants’ anticompetitive conduct, and bars Shkreli from the pharmaceutical industry for life.

Jump to Page

Robins Kaplan LLP Cookie Preference Center

Your Privacy

When you visit our website, we use cookies on your browser to collect information. The information collected might relate to you, your preferences, or your device, and is mostly used to make the site work as you expect it to and to provide a more personalized web experience. For more information about how we use Cookies, please see our Privacy Policy.

Strictly Necessary Cookies

Always Active

Necessary cookies enable core functionality such as security, network management, and accessibility. These cookies may only be disabled by changing your browser settings, but this may affect how the website functions.

Functional Cookies

Always Active

Some functions of the site require remembering user choices, for example your cookie preference, or keyword search highlighting. These do not store any personal information.

Form Submissions

Always Active

When submitting your data, for example on a contact form or event registration, a cookie might be used to monitor the state of your submission across pages.

Performance Cookies

Performance cookies help us improve our website by collecting and reporting information on its usage. We access and process information from these cookies at an aggregate level.

Powered by Firmseek